<DOC>
	<DOC>NCT00788567</DOC>
	<brief_summary>This study will compare the efficacy and safety of 2 dosing regimens of oral CellCept administered as a component of standard immunosuppressive therapy in recipients of kidney transplants. The anticipated time on study treatment is 3-12 months, and the target sample size is 100-500 individuals.</brief_summary>
	<brief_title>CLEAR Study - A Study of CellCept (Mycophenolate Mofetil) in Recipients of Kidney Transplants</brief_title>
	<detailed_description />
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<criteria>adult patients &gt;=18 years of age; recipients of a primary kidney transplant. positive for HIV1, human Tcell leukemia/lymphoma virus1 (HTLV1), or hepatitis B surface antigen; positive for hepatitis C virus, with moderate or severe liver disease; active malignancy or history of malignancy, excluding skin cancer (basal or squamous cell) that has been adequately treated; need for maintenance corticosteroids for another condition.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2015</verification_date>
</DOC>